12 results about "Cefoperazon" patented technology

The invention relates to the field of chemical medicine impurities, and particularly discloses a cefoperazone sodium polymer degradation impurity and a preparation process thereof.The preparation process comprises the steps that cefoperazone sodium serves as a raw material and is subjected to an acylation reaction with pivaloyl chloride, then a product obtained after the acylation reaction reacts with 7-TMCA, and the cefoperazone sodium polymer degradation impurity is obtained. According to the method, cefoperazone sodium is taken as a raw material, cefoperazone sodium polymer degradation impurities are prepared through a synthesis method, the content of the cefoperazone sodium polymer degradation impurities is higher, synthesized components are purer, crystallization and purification are facilitated, a target product with higher purity is prepared, the purity reaches 95.21-99.88%, the yield is 45-50%, the process is simplified, the period is short, operation is easier, and large-scale preparation is easy.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

The present application relates to the field of cefoperazone acid, and discloses a preparation method of cefoperazone impurity A, which comprises the following steps: (1) performing acyl chloride treatment on oxypiperazine acid in the presence of an acyl chloride reagent to generate an acyl chloride compound of oxypiperazine acid; (2) performing silylation treatment on 7-aminocephalosporanic acid in the presence of a silylation reagent to generate a silylated compound of 7-aminocephalosporanic acid; (3) reacting the acyl chloride compound of oxypiperazine acid with the silylated compound of 7-aminocephalosporanic acid to generate an intermediate compound (I); (4) hydrolyzing the intermediate compound (I) under the action of penicillin acylase to generate an intermediate compound (II); and (5) performing esterification and cyclization reaction on the intermediate compound (II) in the presence of a first crystallization solvent, a first organic solvent and a cyclization reagent to obtain the cefoperazone impurity A. The method disclosed by the present application is simple in process, and can obtain the cefoperazone impurity A with high purity, which can be used as a control sample for cefoperazone detection.

This invention discloses a cefoperazone sodium and sulbactam sodium composition and its preparation method, comprising the following steps: preparing a chitosan-β-glycerophosphate sodium colloidal solution; mixing dry ice and sorbitol evenly, then adding the mixture to the colloidal solution, freezing, heating, and drying under reduced pressure to obtain chitosan-β-glycerophosphate sodium nanospheres; slowly adding cefoperazone sodium, sulbactam sodium, and chitosan-β-glycerophosphate sodium nanospheres to water for injection, stirring to dissolve; adjusting the pH to 7.1-7.5, adding an adsorbent for adsorption and filtration, adding dry ice; freeze-drying to obtain a cefoperazone sodium and sulbactam sodium mixed powder. The nanospheres of this invention, with a certain size gradient, are beneficial for the uniformity of the mixed powder of cefoperazone sodium and sulbactam sodium, resulting in a longer-lasting efficacy, better stability, lower hygroscopicity, and also playing an antibacterial role.

This invention discloses a pharmaceutical composition containing cefoperazone sodium and tazobactam sodium for the treatment of renal insufficiency complicated with bacterial infection. The weight ratio of cefoperazone sodium to tazobactam sodium is 6:1. In the treatment of renal insufficiency complicated with bacterial infection, this composition effectively improves clinical efficacy while significantly reducing the incidence of adverse reactions, achieving a good balance between efficacy and safety. This invention also provides a pharmaceutical composition that effectively reduces the production of related substances, significantly improving the product quality of the 6:1 cefoperazone sodium and tazobactam sodium mixture, and further ensuring the stability of the drug during use, storage, and transportation.

The invention relates to the technical field of cephalosporin antibiotics, and particularly discloses a purification method of a cefoperazone acid crude product. The method comprises the following steps: mixing a solvent, a cefoperazone acid crude product, an alkaline reagent and a dispersing agent to obtain a mixed solution; the dispersing agent comprises acetone and acetonitrile; adjusting the pH value of the mixed solution to 3.0-3.5, adding a cefoperazone acid seed crystal, and growing the crystal for the first time; and adjusting the pH value of the system to be 1.5-2.0, and carrying out secondary crystal growing to obtain the cefoperazone acid. Crude cefoperazone acid products are recycled for unqualified products and mother liquor difficult to treat in existing cefoperazone acid production, S-isomer impurities most difficult to separate are specifically and efficiently removed, after purification, the S-isomer content can be reduced to 0.1% or below, the content of other impurities is smaller than 0.10%, the product purity is stabilized to be 99.5% or above, the product yield reaches up to 87%, and the method is suitable for industrial production. The recycling rate of the cefoperazone acid crude product is increased, and the economic and environment-friendly win-win effect is realized.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

The utility model discloses a filling device for cefoperazone sodium and sulbactam sodium, and relates to the technical field of medicine filling equipment. A filling device for cefoperazone sodium and sulbactam sodium comprises a rotating disc set used for bearing and transporting medicine bottles; the supporting frame is arranged on the side edge of the rotating disc set; the lifting assembly is mounted on the supporting frame; the filling assembly is connected with the bottom of the lifting assembly and used for filling the medicine bottles with cefoperazone sodium and sulbactam sodium; the anti-overflow assembly is fixed to the filling assembly and arranged around the medicine bottle by a circle. The problems that mixed powder flies and is wasted, and the filling weight is insufficient are solved.

The invention relates to the technical field of cefoperazone sodium, and particularly discloses a preparation method of a cefoperazone sodium impurity H. The preparation method of the cefoperazone sodium impurity H provided by the invention comprises the following steps: carrying out carboxyl protection reaction on a compound shown in a formula 2 and a compound shown in a formula 3 to obtain a compound shown in a formula 4; carrying out condensation reaction on the compound shown in the formula 4 and a compound shown in a formula 5 to obtain a compound shown in a formula 6; and carrying out carboxyl deprotection reaction on the compound shown in the formula 6 to obtain the cefoperazone sodium impurity H. According to the method, a strategy of precisely controlling a synthesis path is adopted, the limitation of a traditional process is broken through, and efficient directional generation of impurity products is realized. The synthesis method provides an impurity H reference substance for quality control of a cefoperazone sodium preparation, and is beneficial to accurate identification and quantitative analysis of related impurities, so that controllable drug quality is ensured, and clinical medication safety is guaranteed.

The application discloses a detection kit for simultaneously determining the concentrations of 12 kinds of antibiotic drugs in trace serum and application, the 12 kinds of antibiotics including vancomycin, meropenem, imipenem, cilastatin, trimethoprim, linezolid, voriconazole, piperacillin, cefoperazone, sulfamethoxazole, cefepime and ceftazidime; the detection kit comprises pretreatment reagents and a liquid chromatography mobile phase; the pretreatment reagents comprise a protein precipitant and purified water; the protein precipitant comprises 50v / v% of methanol and 50v / v% of acetonitrile; the liquid chromatography mobile phase comprises phase A and phase B, the phase A comprises 0.02% of formic acid and 99.98% of water, and the phase B comprises 100% of acetonitrile. The method of the application only needs 10 muL of human serum sample, and can complete the detection within 4 min, can quantitatively determine 12 kinds of antibiotics with significant structural differences, and is simple, rapid, sensitive, accurate and specific.

The application discloses a kind of adhering arrow bacteria DLW198 and application.It belongs to the technical field of antibiotic degradation.The adhering arrow bacteria DLW198 of the application can tolerate the concentration of cefoperazone is 50-250mg / L, the inoculation amount of adhering arrow bacteria is 5%-25%, the degradation temperature is 20-40 DEG C, and pH is 5-9, under the above conditions, adhering arrow bacteria can effectively degrade cefoperazone.Under the conditions of temperature 30 DEG C, pH 7, inoculation amount 20%, and rotation speed 200r / min, the degradation rate of strain DLW198 to 200mg / L cefoperazone reaches 92.98% in 16h.In addition, strain DLW198 can also degrade cephalexin, ceftriaxone sodium, cefixime and amoxicillin.The strain has higher biological safety, and will not endanger human health or pollute the environment in the application process, and has important application value.